### **Overview** Lupin Limited is an innovation-led, transnational pharmaceutical company headquartered in Mumbai, India, operating in over 100 countries across the U.S., India, South Africa, APAC, LATAM, Europe, and the Middle East. As the **third-largest pharmaceutical company in the U.S. by prescription volume**, Lupin has evolved from a traditional generics player into a globally diversified enterprise with strategic focus areas in complex generics, biosimilars, specialty medicines, and active pharmaceutical ingredients (APIs). The company employs over 20,000 professionals and operates 15 manufacturing sites and 7 global R&D centers. With balanced revenue distribution—approximately **50% from Developed Markets** (primarily U.S., Canada, Europe, Australia) and **50% from Emerging Markets** (India, South Africa, Brazil, Mexico, Philippines, and access markets)—Lupin continues to strengthen its competitive edge through innovation, strategic acquisitions, and vertical integration. --- ### **Strategic Focus & Business Segments** #### **1. Global Expansion & Market Leadership** Lupin's growth strategy emphasizes: - **India**: Leadership in chronic disease therapies (cardiology, diabetes, respiratory, and GI), supported by a field force of over 10,000 representatives. - **U.S.**: Transition from commoditized generics to high-barrier **complex generics and specialty products**, including respiratory therapies, injectables, and biosimilars. - **EMEA & Other Developed Markets**: Strategic expansion via acquisitions and product launches, targeting respiratory, neurology, and injectables. - **Emerging Markets**: Profitable, self-sustaining operations in South Africa (ranked #1 in cardiovascular), Brazil, Mexico, and the Philippines, with strong local market penetration. **Global Revenue Mix (FY25 estimates):** - United States: ~34% - India: ~34% - Other Developed Markets (Europe, Canada, Australia): ~13%–15% - Emerging Markets: ~11% - Global Institutional Business (TB/HIV): Growing contributor --- ### **Recent Strategic Moves (2025)** #### **Acquisition of VISUfarma (September 2025)** - **Deal Value**: €190 million enterprise value. - Lupin acquired **100% stake in VISUfarma**, a pan-European specialty ophthalmology company with commercial presence in EU4+UK and 20+ markets. - **Key Highlights**: - Establishes direct commercial operations in all major EU countries. - Creates a **pan-European ophthalmology platform**, enabling synergies with Lupin’s existing EU footprint. - Enhances pipeline with over **60 branded ophthalmic products (OTx & Rx)**. - VISUfarma generates **€54 million estimated revenue in 2025**. - Supports future expansion into Southeast Asia. - Deal expected to be accretive to sales growth and EBITDA margin; expected closing by end of 2025. #### **Spin-offs & Strategic Restructuring** As part of a broader strategy to sharpen focus and unlock value: - **Lupin Life Sciences (LLS)**: Carved out as a standalone subsidiary focused on **trade generics** in India, targeting fast-growing tier 2/3 towns. Portfolio includes 350 affordable products; aims for high double-digit growth. - **LupinLife Consumer Healthcare Limited**: New subsidiary housing OTC brands. Flagship product **Softovac® holds 42% market share in bulk laxatives** in India. Plans for rapid scale-up. - **Lupin Manufacturing Solutions (LMS)**: Consolidated CDMO arm combining API Plus and contract development operations, offering services in peptides, ADCs, and complex molecules. Backed by manufacturing hubs in Vizag and Dabhasa, and an advanced R&D center in Pune. --- ### **Therapeutic & Product Focus** #### **1. Complex Generics & Specialty Franchise** Complex generics now represent **35% of U.S. revenue** (projected to reach ~50% by FY30) and **55% of EMEA revenue**, driving resilient growth amid oral solid pricing pressures. **Key Growth Platforms:** - **Respiratory**: 25–40% of U.S. revenue, driven by Albuterol, Tiotropium, Brovana®, and Xopenex®. - **Injectables**: Expanding portfolio; key upcoming U.S. launches include **Glucagon, Risperdal Consta, and Liraglutide**. - **Ophthalmics**: Strengthened by VISUfarma and internal pipeline including biosimilars. - **Biosimilars**: Emerging platform with global scale; key assets: Etanercept, Ranibizumab, Aflibercept, and Pegfilgrastim. #### **2. Biosimilars Pipeline (2025–FY30)** Lupin is building a **global biosimilars platform** across U.S., EU, Canada, Australia, and India, focusing on first-mover advantage and exclusivity. **Key Pipeline Milestones:** - **Ranibizumab & Aflibercept** biosimilars: Expected commercial launch in **FY27 and FY28**, respectively; limited competition offers strong growth potential. - **Etanercept**: Launched in several international markets; planned entry into U.S. in **FY29**, as one of four expected entrants despite pricing headwinds from the Inflation Reduction Act. - **Mepolizumab & Benralizumab (respiratory)**: In development for U.S. and EU markets. - **Certolizumab pegol**: Advanced to clinical development. - **Pembrolizumab & Nivolumab biosimilars**: Under development in India for immuno-oncology. #### **3. Chronic Care Innovation (India & Global)** Lupin is positioning itself as a **chronic disease care leader**: - Strengthened diabetes portfolio via acquisitions of **Huminsulin® (Eli Lilly)** and **Gibtulio®, Ajaduo® (Boehringer Ingelheim)**. - Targeting **GLP-1 therapies** as a core growth vector in India and globally. - Expanding into **Gastroenterology (GI)** as its fourth major therapy area. - Growing presence in **Oncology, CNS, and VMS (vitamins, minerals, supplements)**. --- ### **R&D & Innovation** - **R&D Investment**: 7.5%–8.5% of revenue targeted for FY26 (~INR 1,800 crores in FY25). - **Focus**: ~70% of R&D on complex and specialty products. - **Pipeline Strength**: - Over **60 U.S. regulatory filings planned**, including 30+ Para IV and First-to-File opportunities. - **100+ new products to be launched in the U.S. by FY30**. - Advancing **505(b)(2) applications**, long-acting injectables, implants, and green propellant inhalers. #### **AI & Digital Innovation** - Partnering with AI providers to accelerate **drug discovery, clinical success prediction, and target identification**. - **Generative AI pilots** in commercial ops, manufacturing, and GMP processes showing promise; scaling globally by FY26. - **Anya**, an AI-powered health chatbot, has addressed over 32 lakh patient queries in six languages. - Digital platforms like **SmartRep, DigiEngage, and GP Konnect** support 100,000+ HCPs. --- ### **Manufacturing & Quality** - **API Powerhouse**: Over 50% of generic products benefit from in-house API integration. - **Global Compliance**: Recent EU-GMP certifications for **4x2KL mammalian facility (Pune)** and **Mihan filling plant**, supporting biosimilar supply. - **Sustainability & Green Chemistry**: Reduced solvent, water, and waste in API processes; E-factor improved from 16.5 to 7.96 for one key molecule. - **LMS Expansion**: MPP-4 (Vizag) operational; MPP-3 (high-potency oncology) reactivated. --- ### **Emerging Adjacencies & Patient-Centric Care** Lupin is extending beyond pharmaceuticals into **holistic healthcare ecosystems**: - **Lupin Diagnostics**: - 44 labs across India; NABL-accredited. - Growing at a **44% YoY revenue growth**; on track for EBITDA break-even by FY27. - 150,000+ patients served monthly; smart reports with trend analytics. - **Lupin Digital Health (LDH)**: - **LYFE® Platform**: First evidence-based digital therapeutics for **cardiac rehabilitation**. - **LYFE HF**: For heart failure management. - Aims to reach **100,000 patients by FY30**; regulatory approval from CDSCO (Class C SaMD). - **Atharv Ability**: - Neuro-rehabilitation centers; delivered 40,000+ therapy sessions. - Opened new facility in Hyderabad; national expansion underway. --- ### **Public Health Leadership** - **Global Tuberculosis (TB) Care**: - **World’s largest supplier of anti-TB medicines** and preventive treatments. - Launched **first WHO-prequalified 150mg dispersible Rifapentine tablet for pediatric TB**. - Supplies Bedaquiline, Pretomanid, and Rifapentine-based regimens; reduced treatment costs by **25–33%**. - Partnered with TB Alliance to manufacture and distribute **Pretomanid** in >140 countries. - **Antiretroviral (ARV) Portfolio**: - WHO-prequalified and approved under PEPFAR. - Supplies to Global Drug Facility, UNDP, MSF, PAHO. --- ### **Commercial Performance & Growth Outlook** #### **Financial Highlights (FY25 Estimates)** | Market | Revenue (Approx.) | Key Products / Drivers | |------------------------|-------------------------|-----------------------------------------------| | **U.S.** | $925 million | Complex generics, Tolvaptan, Albuterol, Brovana®, Xopenex® | | **India** | ~34% of global sales | Chronic therapies, NaMuscla®, Huminsulin®, digital initiatives | | **Europe** | $195 million | Luforbec®, NaMuscla®, Etanercept, biosimilars | | **Canada** | $47 million | Zaxine®, Relistor®, Intrarosa®, Tiotropium | | **Australia** | $78 million | Generic Health subsidiary; strong CAGR | | **South Africa** | $83 million | Cardiovascular #1, CAMS OTC growth | | **Mexico** | $49 million | Ophthalmology #3, Grin portfolio | | **Brazil** | $42 million | Retail reference market #3 | | **Philippines** | ~$40 million | Multicare; #2 in reference market | #### **U.S. Business** - 138 marketed products; **105 rank among top 3**, **45 are #1**. - 13% YoY growth in FY25 after turnaround. - Recently launched generic **Victoza® (liraglutide)** and **Glucagon**, making Lupin the **first Indian company to launch a GLP-1 generic in the U.S.**. - Tolvaptan (180-day exclusivity) launched in FY26; high-margin specialty opportunity.